The mission of ViroStatics is to leverage the team's rich history of success in scientific research and the development of intellectual properties to commercialize immunotherapeutic agents and novel drug combinations as innovative treatments to combat HIV/AIDS, viral infections, cancer, and other global diseases.
The Company's focus is the development of AntiViral-HyperActivation Limiting Therapeutics (also known as "AV-HALTs") - rationally designed products that directly target disease-causing pathogens while also supporting the individual's immune system.
ViroStatics' lead product in clinical development, VS411, has recently completed a multinational Phase II Proof-of-Concept study as a treatment for HIV/AIDS. Over the 28 days of the study, VS411 safely lowered HIV replication by 1.5 logs (96.8%) without inducing drug resistance, significantly increased CD4+ T cells by up to 135 cells/mm3 in the dideoxyinosine 200 mg/hydroxycarbamide 900 mg cohort (doses lower than traditionally investigated). VS411 also rapidly and significantly reduced four key markers of excessive immune activation, becoming the first HIV/AIDS therapy to achieve both goals of an AV-HALT after only four weeks of therapy.
ViroStatics has obtained an exclusive license to a library of 300 compounds consisting of specifically designed molecules targeting key enzymes and processes involved in both cancer and viral diseases. In addition, the Company has formed a partnership with Vichem Chemie of Budapest, Hungary to identify, synthesize, screen, and develop the next generation of AntiViral-HyperActivation Limiting Therapeutics (AV-HALTs) for the treatment of HIV/AIDS and other chronic diseases. Our scientists are working to identify and develop candidate compounds with activity against HIV (the virus that causes AIDS), hepatitis C, and other viruses and seeks partners for the development of these compounds in the oncology space where in vivo proof of concept has been shown for Burkitt's lymphoma and osteosarcoma as well as in imatinib (GleevecŪ) resistant [T315I] CML and ALL.
ViroStatics has also developed novel biomarker assays and a proprietary screening methodology to rapidly and efficiently identify cytostatic agents with potential to inhibit viral replication and control the over-stimulation of the immune system that is believed to drive the progression of HIV to AIDS.
ViroStatics is committed to expanding its pipeline and product portfolio by in -licensing early- and late-stage compounds and exploring co-development opportunities that fit the Company's expertise in specialty pharmaceuticals and biopharmaceuticals.
With offices in Sassari, Italy and Princeton, New Jersey, USA, ViroStatics continues the international approach to combating disease of our corporate parent, the Research Institute for Genetic and Human Therapy. |
